Therapeutic quassinoid preparations with antineoplastic antiviral, and herbistatic activity
AssigneeAdvanced Research and Technology Institute, Inc.
InventorsPaul A. Grieco, D. James Morre, Thomas H. Corbett, Frederick A. Valeriote
Life of this patent
Estimating the term…
Abstract
The present invention includes purified and isolated quassinoids and synthetically derived quassinoid analogs based on a picrasane carbon skeleton. Novel sidechains at C-15 incorporating water solubilizing agents such as glycine are discussed. Therapeutic methods taking advantage of anticancer, antiviral, and herbistatic properties of these quassinoids are disclosed, including use against solid tumors and human immunodeficiency virus infected cells.
Claims13
A method for treating solid tumors comprising the steps of preparing a pharmaceutically active composition containing a quassinoid represented by the formula ##STR13## wherein R.sub.1 represents a hydroxyl, R.sub.2 and R.sub.4 represent double bonded oxygen, R.sub.3 represents hydrogen, oxygen, alkyl, alkenyl, acyl, aryl, halogen, sulfo, nitro, carboxyl, hydroxyl, hydroxyalkyl, alkoxy, or other water soluble sidechain, and Y is a sidechain comprising hydrogen, oxygen, halogen, hydroxyl, ester, carbonyl, alkyl, hydroxyalkyl, aryl, glycine, glycosaccharides, water soluble sidechains, amino acid, peptide, polypeptide, protein, and any of the foregoing attached to the C-15 carbon by an ether, ester, carbonyl, or glycosidic linkage, and
- contacting the solid tumors with said pharmaceutically active composition.
A method for inhibiting NADH oxidation to control cellular activity comprising the steps of preparing a pharmaceutically active composition containing a quassinoid represented by the formula ##STR16## wherein R represents hydrogen, oxygen, alkyl, alkenyl, acyl, aryl, halogen, sulfo, nitro, carboxyl, hydroxyl, hydroxyalkyl, alkoxy, or other water soluble sidechain, and Y is a sidechain comprising hydrogen, oxygen, halogen, hydroxyl, ester, carbonyl, alkyl, hydroxyalkyl, aryl, glycine, glycosaccharides, water soluble sidechains, amino acid, peptide, polypeptide, protein, and any of the foregoing attached to the C-15 carbon by an ether, ester, carbonyl, or glycosidic linkage, with the proviso that said quassinoid is not ailanthinone, glaucarubinone, chaparrinone, glaucarubolone, castelanone, soularubinone, holacanthone, glaucarubolone-15-benzoate, 2'-acetylglaucarubinone, or glaucarubolone-15-tiglate, and with the further proviso that said Y is not a C.sub.5 to C.sub.18 2-alkenoate or a C.sub.5 to C.sub.16 3-methylalkenoate, and
- contacting the cells with said pharmaceutically active composition to modify NADH oxidation.
A method for inhibiting NADH oxidation to control cellular activity comprising the steps of preparing a pharmaceutically active composition containing a quassinoid represented by the formula ##STR17## wherein R represents hydrogen, oxygen, alkyl, alkenyl, acyl, aryl, halogen, sulfo, nitro, carboxyl, hydroxyl, hydroxyalkyl, alkoxy, or other water soluble sidechain, and Y is a sidechain comprising hydrogen, oxygen, halogen, hydroxyl, ester, carbonyl, alkyl, hydroxyalkyl, aryl, glycine, glycosaccharides, water soluble sidechains, amino acid, peptide, polypeptide, protein, and any of the foregoing attached to the C-15 carbon by an ether, ester, carbonyl, or glycosidic linkage, with the proviso that said quassinoid is not simalikalactone D or quassimarin, and
- contacting the cells with said pharmaceutically active composition to modify NADH oxidation.
Dependencies are inferred from the claim text.